Abattis Bioceuticals will have access to Suzhou Raybot Material Tech’s extraction technology thanks to a new distribution agreement between the two companies.
Abattis Bioceuticals (CSE:ATT, OTCQB:ATTBF) will have access to Suzhou Raybot Material Tech’s extraction technology thanks to a new distribution agreement between the two companies.
As quoted in the press release:
Raybot has developed a proprietary technology which utilizes industrial column chromatography to extract and separate a wide range of materials, in a continuous, closed loop system. This method, which is currently used in the mass production of extracts, such as Ginkgo Biloba, Stevia, and Ginsenosides, among others, has been specifically designed for the extraction of legal cannabis derivatives, such as Cannabidiol (“CBD”), Tetrahydrocannabinol (“THC”), and Cannabigerol (“CBG”), from Marijuana or Hemp. The technology has excellent processing capacity, high extraction yield, and significant cost advantages over traditional methods.
The proprietary technology is capable of extracting CBD from Hemp to above a 99% purity level. The current methods using multi-staged CO2 extraction are significantly more expensive and limited in production scale. Raybot’s extraction machines can be customized to any factory production scale. A factory with 5,000 kg per day processing rate is able to produce CBD at $0.20 per gram.
“This technology has the potential to revolutionize the extraction process for THC, CBD, CBG and other cannabis derivatives globally,” stated Robert Abenante, President and CEO of Abattis. “Raybot’s proprietary extraction method is currently one of the only toll processing technologies that can extract high purity CBD on an industrial scale. Furthermore, it could lead to the full separation of individual compounds and derivatives at significantly lower costs than today’s widely used methods.”